Doripenem: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Doripenem}} | {{Doripenem}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Overview== | ==Overview== | ||
Revision as of 22:05, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Overview
Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup carbapenem. It was launched byShionogi Co. of Japan under the brand name Finibax in 2005. It is particularly active against Pseudomonas aeruginosa.
Category
Carbapenem
US Brand Names
DORIBAX®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Doripenem belongs to the carbapenem class of antimicrobials. Doripenem exerts its bactericidal activity by inhibiting bacterial cell wall biosynthesis. Doripenem inactivates multiple essential penicillin-binding proteins (PBPs) resulting in inhibition of cell wall synthesis with subsequent cell death. In E. coli and P. aeruginosa, doripenem binds to PBP 2, which is involved in the maintenance of cell shape, as well as to PBPs 3 and 4.